Introduction Aneurysmal subarachnoid hemorrhage (SAH) has a poor outcome, particularly attributed to progressive injury after the initial incident. Several studies suggest a critical role for inflammation in lesion progression after SAH. Our goal was to test whether treatment with anti-inflammatory interferon-b, which has shown promise as a therapeutic agent in experimental ischaemic stroke, can protect the brain after SAH. Methods SAH was induced in adult male Wistar rats by puncturing the intracranial bifurcation of the right internal carotid artery. Treatment effects of daily interferon-b (n = 16) or vehicle (n = 14) injections were serially evaluated with multiparametric MRI and behavioral tests from day 0 to 7, in compliance with recent recommendations for pre-clinical drug testing. Outcome measures included neurological status, brain lesion volume, blood-brain barrier (BBB) leakage, and levels of inflammatory markers. Results In animals that survived up to 7 days post-SAH, we found no significant differences between vehicle-and interferon-b-treated animals with respect to final neurological score (14.3 ± 1.0 vs. 13.0 ± 2.2), brain lesion size on T 2 -weighted MR images (59 ± 83 vs. 124 ± 99 mm 3 ), BBB leakage (0.26 ± 0.05 vs. 0.22 ± 0.08 contrastinduced relative MR signal change), upregulation of brain RNA for cytokines, chemokines and cell adhesion molecules, and increased neutrophil activation. Conclusions In contrast to previously published findings in experimental ischemic stroke models, interferon-b has no clear efficacy to protect the brain after SAH. In line with recent highlighting of the significance of negative findings, our data currently do not recommend clinical testing of interferon-b to prevent neurological damage in SAH patients.
Introduction
Aneurysmal subarachnoid hemorrhage (SAH) has an incidence of 6-7 per 100,000 and carries a poor outcome: average case fatality is about 50 % and survivors frequently remain dependent [1] . Delayed cerebral ischaemia (DCI) develops in the first days to weeks after the initial bleeding and is the most important cause of poor outcome in SAH patients who survive the first 24 h [1] . Advanced brain injury after SAH has been recognized to be associated with early brain injury during the first few days as well as subsequent DCI [2] .
An increasing amount of data suggests that cerebral inflammation is a major factor in advanced brain injury after SAH, as reviewed by Provencio and Vora [3] . SAH leads to an increase in plasma and cerebral spinal fluid (CSF) levels of cytokines, cell adhesion molecules and leukocytes, which has been correlated with early brain injury, DCI and subsequent poor outcome [3] . Hence, several treatment strategies against advanced brain injury have been aimed at suppressing the inflammatory response after SAH. Broad-acting immunosuppressive drugs like corticosteroids, as well as non-steroidal anti-inflammatory drugs have shown mixed effects in animal and clinical studies [4] . It has been speculated that the interaction between leukocytes and brain endothelium, and subsequent transendothelial migration, particularly contribute to progression of brain injury [3, 4] . Therefore, reduction of leukocyte infiltration may be an effective approach to reduce the progression of brain injury after SAH. A potential candidate for anti-inflammatory treatment against advanced brain injury after SAH is the cytokine interferonb. Interferon-b is established in the treatment of relapsingremitting multiple sclerosis (MS) [5] . It has been shown to effectively suppress leukocyte diapedesis, possibly through stabilization of the blood-brain barrier (BBB) [6] . Interferon-b has demonstrated beneficial effects in animal models of ischaemic stroke [7, 8] , in which it blocked poststroke invasion of inflammatory cells, confined leakage of the BBB and significantly reduced final infarct size [7] .
We hypothesized that interferon-b treatment after SAH would inhibit the inflammatory response, reduce cerebral damage and improve neurological outcome, similar to its efficacy in experimental ischaemic stroke models. Therefore, we longitudinally measured the development of cerebral inflammation, brain injury, and behavioral status after experimental SAH in rats treated with interferon-b or vehicle.
Methods

Animals
Male Wistar rats (Harlan, Horst, The Netherlands) weighing 320-350 g, were used. The Animal Experiments Committee of the University Medical Centre Utrecht and Utrecht University approved experiments conducted for this research.
Experimental SAH
Rats were anesthetized by mechanical ventilation with 2 % isoflurane in air/oxygen (2/1) and received an intramuscular injection of 5 mg/kg (10 mg/ml) gentamicin (Centrafarm, Etten-Leur, The Netherlands) to prevent infection. Core temperature was maintained at 37.5°C using a temperature-controlled heating pad. SAH was induced as previously described [9] . In brief, a sharpened 4.0 Prolene suture was advanced into the right internal cerebral artery (ICA) up to the bifurcation of the ICA and middle cerebral artery (MCA), where the Circle of Willis was perforated (SAH group). In sham-operated animals the suture was moved up to the intracranial ICA bifurcation, without puncturing the vessels (SHAM group). After withdrawal of the suture and wound closure, animals received 0.03 mg/kg (0.03 mg/ml) buprenorphine (Reckitt & Colman, Kingston-Upon-Hill, UK) for pain relief.
Daily weight loss was monitored and weight loss over 10 g per 24 h was compensated for by subcutaneous injection of 5-15 ml Ringer's lactate (Baxter, Utrecht, The Netherlands).
Treatment
Animals were treated with daily subcutaneous injections of 26 lg/kg rat recombinant interferon-b (U-Cytech, Utrecht, The Netherlands) or vehicle (0.4 % rat serum and 25 mmol/ml trehalose in PBS; pH 7), with the first injection at 2 h after SAH and the fourth and last injection 3 days thereafter. Production and purification of interferonb were done as previously described [7] . Bioactivity of the interferon-b batch was verified with an antiviral bioassay [10] . Dosage was similar to doses that significantly reduced the inflammatory response and lesion size after experimental autoimmune encephalomyelitis [11] , experimental neuroinflammation [12] , and experimental cerebral ischaemia in rats [7] .
Outcome Measurements
Primary outcome measures were lesion volume on T 2 -weighted MRI and behavioral outcome. Secondary outcome measures were BBB integrity, cerebral inflammation and SAH severity.
Behavioral Assessment of Neurological Status
Neurological deficits were measured before SAH (day 0) and at days 1, 2, 3, and 7 post-SAH with a modified version of the method described by Sugawara et al. [13] . Animals were scored on spontaneous activity (scores 0-3), activity of extremities (scores 0-3), forepaw outstretching (scores 0-3), climbing reflex (scores 1-3), and a forepaw placing response to the vibrissae touching the table side (scores 1-3). Maximum score was 15 (absence of deficits).
In addition, rats were placed on a triplex surface plane with 30°inclination to test their ability to keep from sliding down during 5 s. Subsequently, the inclination was increased by 5°to score the maximum inclination at which the animal was able to maintain its posture [14] .
MRI of Lesion Volume and BBB Integrity
MRI experiments were conducted at days 2 and 7 on a Varian (Palo Alto, CA, USA) 4.7 T horizontal bore MR system, with a 90 mm Helmholtz volume coil and inductively coupled 25 mm surface coil for radiofrequency signal transmission and detection, respectively. Anesthesia was maintained by isoflurane in the same manner as described above. Animals were positioned in a rat holder. Core temperature was maintained at 37.5°C. Blood oxygenation, heart rate, and expired CO 2 were constantly monitored and kept within physiological range.
For lesion detection, we applied T 2 -weighted MRI (multiple spin echo; repetition time (TR) 3,600 ms; echo time (TE) 15-180 ms; field-of-view (FOV) 32 9 32 9 19 mm 3 ; data matrix 256 9 128 9 19; number of acquisitions (NA) 2).
BBB leakage was measured at day 7, from T 1 -weighted MRI (gradient echo; TR 160 ms; TE 4 ms; FOV 32 9 32 9 19 mm 3 ; matrix size 256 9 128 9 19; NA 8) acquired before and after intravenous (tail vein) administration of 0.35 mmol/kg gadobutrol (Schering, Keniworth, NJ, USA). Post-contrast T 1 -weighted MRI was started 160 s after injection and repeated every 165 s for 22 min (eight runs).
T 2 maps were computed by mono-exponential fitting of T 2 -weighted MRI data. Lesions were identified as brain tissue with significant T 2 prolongation, and automatically segmented. The lower threshold for lesion classification was the mean brain tissue T 2 in SHAM animals plus two times the average standard deviation. An upper threshold to minimize CSF contribution was defined as the 95th percentile of the T 2 distribution in manually outlined lesions. Possible false-positives due to partial volume effects from remaining CSF signal were detected in SHAM animals, and counted up to an average volume of 143 (±27) and 145 (±32) mm 3 at days 2 and 7, respectively. These values were subtracted from segmented lesion volumes in SAH animals to correct for residual CSF contamination.
BBB leakage in the brain was established at day 7 from post-contrast T 1 -weighted signal enhancement at 25 min after gadobutrol administration. The difference in signal intensity between pre-and post-contrast images was calculated relative to the pre-contrast signal intensity.
Biochemical Assays of Cerebral Inflammation
After MRI at day 7, animals were sacrificed by an intravenous overdose of pentobarbital (Alfasan, Woerden, The Netherlands). Brains were excised, divided into two cerebral hemispheric halves and subsequently snap-frozen in liquid nitrogen. Thereafter, tissue was mechanically pulverized, divided into fractions and stored at -80°C.
Myeloperoxidase (MPO) activity, as a measure of neutrophil accumulation [15] , was determined by an inversion method of the substrate 3,3 0 ,5,5 0 -Tetramethylbenzidine dihydrochloride dehydrate (Sigma Aldrich, Steinheim, Germany) a described previously, and expressed as U/ml brain homogenate [16] . For quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis, RNA was isolated from pulverized tissues with trizol reagent (Invitrogen, Paisley, UK). cDNA was synthesized from total RNA with SuperScript Reverse Transcriptase kit (Invitrogen, Paisley, UK). Quantitative real-time RT-PCR reaction was performed with iQ5 RT-PCR Detection System (Biorad, Hercules, CA, USA) using rat primers for tumor necrosis factor-a (TNF-a), macrophage inflammatory protein-1/CC motif chemokine 3 (CCL3), macrophage inflammatory protein-2 (MIP-2), cytokine-induced neutrophil chemoattractant (CINC), E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1). To confirm appropriate amplification, size of RT-PCR products was verified on gel. Data were normalized for expression of internal controls, b-actin and GAPDH.
Post-mortem SAH Severity Scoring
Brains of animals that died before the end of the experimental protocol were extracted within 24 h after death. Photographic pictures were taken from the base of the brain. To score SAH severity, a grid dividing the basal cistern in six segments was overlaid on the pictures, and each segment was allotted a grades of 0-3 depending on the amount of blood (Grade 0: no subarachnoid blood; Grade 1: minimal subarachnoid blood; Grade 2: moderate clot with recognizable arteries; and Grade 3: blood clot obliterating all arteries within the segment) [13] . Total score (0-18) was the sum of the six segments.
Group Assignment and Inclusion Criteria
All experimental procedures were done according to good laboratory practice [17] . To determine group sample size, we projected a treatment-induced lesion size reduction of 50 %, based on a previous study that assessed the effect of similar interferon-b doses on ischaemic injury [7] , with a standard deviation of 30 % [9] . With a = 0.05 and b = 0.2, this resulted in a group sample size of seven. We anticipated a model-specific mortality of 50 % [18] and therefore included a total of 15 animals per group.
The executive researcher (IT) was blinded for treatment allocation. Treatment was randomly assigned by a second researcher (RZ) who did not participate in acquisition and analysis of outcome measures. Treatment assignment was revealed to the executive researcher after all assessments and full data processing was completed.
All animals that survived until onset of treatment and did not die as a result of technical complications, e.g., endotracheal tube obstruction during MRI, were included. Successful SAH (n = 30) (and sham) surgery was confirmed by inspection of (absence of) vessel wall perforation after brain dissection. SHAM animals (n = 9; 5 vehicle and 4 treated with interferon-b) were used for reference qRT-PCR analysis and calculation of normal tissue T 2 values.
Statistics
Statistical analysis included two-way repeated measures ANOVA for testing treatment effect on development of lesion volume and inclined plane score. A student's t test was used to compare weight changes, and BBB-associated gadobutrol leakage, between interferon-b-and vehicle-treated animals. A Mann-Whitney U test was used to compare neurological scores and SAH severity scores between treatment groups. For group comparisons of levels of inflammatory markers, a two-way ANOVA with post hoc Bonferroni-testing was used to test SAH vs. SHAM animals, and interferon-b vs. vehicle treatment. A log-rank test was used to test for difference in survival rate between the two treatments. Values are shown as mean ± SD or median (25-75th percentile), and P < 0.05 was considered significant.
Results
Out of 30 animals in which SAH was successfully induced, 14 animals were assigned to the vehicle group, of which seven completed the entire experimental protocol, while 16 animals were assigned to the interferon-b group, of which six completed the protocol. Seven animals were excluded from the study due to technical complications. The SHAM group consisted of five vehicle-and four interferon-btreated animals.
Bioactivity of interferon-b was 8 9 10 7 U/mg protein. Animals exhibited some weight loss as a result of the experimental protocol, which was somewhat higher in interferon-b-treated SHAM and SAH rats (percent weight loss from day 0-7: 7 ± 4 and 13 ± 6 %, respectively) as compared to their vehicle-treated counterparts (percent weight loss from day 0-7: 3 ± 3 and 8 ± 4 %, respectively).
Neurological Status
The first days after SAH, animals exhibited clear neurological deficits, which partially recovered thereafter ( Fig. 1  (left) ). The neurological deficiency score was most strongly reduced at day 1, and gradually recovered thereafter. There was no significant difference in scores between functional vehicle-and interferon-b-treated rats.
The highest inclination at which animals were able to remain their posture had significantly declined at days 1, 2, and 3 after SAH in both treatment groups, as compared to baseline measurements (P < 0.05) (Fig. 1 (right) ). Furthermore, interferon-b-treated animals had significantly lower inclination scores than vehicle-treated animals (P < 0.05).
Lesion Volume
Brain T 2 maps displayed areas with T 2 prolongation, particularly at day 2 in SAH animals in both treatment groups Fig. 1 Graphs displaying neurological score (left) (median ± quartiles) and inclined plane score (right) (mean ± SD) at different time-points after SAH in vehicle-and interferon-b-treated rats.
Interferon-b-treated animals have significantly lower inclination scores than vehicle-treated animals (P < 0.05) (Fig. 2 ). Brain T 2 lesions were observed in the ipsilateral sensorimotor cortex in 94 % of SAH rats at day 2. In addition 81 % of SAH animals had lesions in the ipsilateral striatum or hypothalamic region. The lesion extended to the contralateral sensorimotor cortex in 69 % of the SAH group (see Fig. 3 , which shows representative examples of segmented areas with significant T 2 prolongation at days 2 and 7 post-SAH). Mean CSF-corrected T 2 lesion volumes at days 2 and 7 in the two treatment groups are displayed in Fig. 4 (left) . The automatically segmented lesion volumes closely matched with results from manually defined lesion outlines (data not shown). The T 2 lesion size declined significantly between days 2 and 7 after SAH (P < 0.05).
We found no significant difference in lesion volume between treatment groups.
BBB Integrity
Post-contrast T 1 -weighted MRI at day 7 revealed brain areas with clear signal increase after intravenous gadobutrol injection, indicative of BBB leakage (see Fig. 3 , which shows a representative example of relative T 1 -weighted signal increase after gadobutrol injection at day 7 post-SAH). Regions that exhibited contrast leakage were typically inside the T 2 lesion area. Figure 4 (right) shows the average relative change in T 1 -weighted signal in the brains 
Cerebral Inflammation
The relative brain amount of RNA synthesis for TNF-a, CCL3, MIP2, CINC, E-selectin, VCAM, and ICAM, and absolute amounts of MPO, are displayed in Fig. 5 . Transcription of TNF-a, CCL3, MIP2, VCAM, and ICAM was significantly upregulated after SAH as compared to SHAM animals (P < 0.05). CINC and E-selectin did not demonstrate a significant increase in upregulation. We found no significant effect of interferon-b on the expression of any of these factors, as compared to vehicle treatment.
Neutrophil infiltration, characterized by MPO content, was close to zero in SHAM animals. However, a significant rise was evident in animals that had suffered from SAH (P < 0.05). Interferon-b treatment did not alter this response as compared to vehicle.
SAH Severity
All animals that did not survive the study protocol died within the first three days after SAH. Although case fatality in the interferon-b group (63 %) was higher than in the vehicle group (50 %), the survival curves did not differ between both groups (Fig. 6 (left) ).
A total of 13 animals that died before completing the protocol were suitably scored on blood deposition to rate SAH severity as displayed in Fig. 6 (right) . Interferon-btreated animals had a median SAH severity score of 8.5 (7.3-11.0) (n = 8), while a significantly higher score of 12.0 (11.0-14.0) (n = 5) was found in the vehicle group (P < 0.05). Fig. 3 Magnetic resonance images of a coronal brain slice of an interferon-b-treated rat at days 2 and 7 after SAH. The brain lesion is identified as hyperintense on T 2 maps (top two images in left column), which was demarcated by automated segmentation (hatched area on T 2 maps in right column). The bottom image in the left column displays relative T 1 -weighted signal enhancement (rDT 1 W) at 25 min after intravenous gadobutrol injection, with clear indication of leakage in the ipsilateral striatum Fig. 4 Left bar graph of volumes of automatically segmented T 2 lesions at days 2 and 7 after SAH in vehicle-and interferon-b-treated rats (left) (mean + SD). T 2 lesion volumes are significantly lower at day 7 as compared to day 2 (P < 0.05), but there is no difference between treatment groups. Right bar graph of relative T 1 -weighted signal change in the entire brain of vehicle-and interferon-b-treated rats at 7 days post-SAH, 25 min after contrast agent injection (mean + SD). There is no significant difference in leakage of contrast agent between the treatment groups Fig. 5 Bar graphs of relative RNA quantity for tumor necrosis factora (TNF-a), macrophage inflammatory protein-1/CC motif chemokine 3 (CCL3), macrophage inflammatory protein-2 (MIP2), CINC, E-selectin, VCAM, and intercellular adhesion molecule-1 (ICAM), and MPO content, at 7 days after SAH or sham-operation, that was followed by vehicle or interferon-b (IFN-b) treatment (mean + SD). Expression is significantly upregulated for SAH as compared to SHAM animals for TNF-a, CCL3, MIP2, VCAM, ICAM, and MPO (P < 0.05). There is no significant effect of interferon-b treatment on any of the inflammatory markers c Neurocrit Care (2013) 18:96-105 101
Discussion
In this study, we found no indication that treatment with interferon-b reduces brain lesion formation, improves neurological outcome, or increases survival rate through chronic reduction of cerebral inflammation after experimental SAH in rats.
Our study was designed to test the hypothesis that immunosuppression by interferon-b would improve outcome in a model that most closely resembles clinical aneurysmal SAH [18] . To ensure optimal translation of our data to the clinical situation, we followed recommendations of the Stroke Therapy Academic Industry Roundtable (STAIR), considering well-defined inclusion and exclusion criteria, and using multiple endpoints that are translatable to the clinic, e.g., MRI-based lesion size and behavioral outcome [19] . Furthermore, to prevent bias we performed a priori sample size calculation, treatment randomization, allocation concealment and blinded assessment of outcome, as recently pointed out [17, 20] .
Brain Injury and Inflammation
Unilateral endovascular perforation of the circle of Willis in rats resulted in lesions that involved ipsi-as well as contralateral cortical and subcortical tissue, as previously described [10, 21] . Significant T 2 prolongation after 2 days denoted oedematous tissue, which declined thereafter, suggestive of oedema resorption at later stages. Significant BBB injury at day 7 was evident from contrast agent leakage into the brain. We observed no effect of interferon-b on the size and progression of the brain lesion between days 2 and 7 post-SAH. Moreover, although the same dosage of interferon-b has been shown to accomplish stabilization of the BBB in rats with a cerebral ischaemic infarction [7] or neuroinflammatory lesion [12] , it failed to reduce BBB leakage chronically after experimental SAH in our study. Inflammation is a critical factor in progressive brain injury after SAH [3, 4] . Our data demonstrate that animals had marked upregulation of RNA for cytokines, chemokines and cell adhesion molecules in the brain at 7 days after experimental SAH. These inflammatory factors are involved in the recruitment, attachment and diapedesis of leukocytes. Furthermore, highly elevated MPO content in the brain after SAH, reflected significant neutrophil infiltration. Despite its immunosuppressive and anti-inflammatory properties, treatment with interferon-b did not result in long-term reduction of the upregulation of inflammatory markers in the brain after SAH, which most probably explains the absence of an effect on ultimate lesion formation and BBB disruption. This cannot be attributed to lacking biological activity, as a significant anti-inflammatory effect has been found in the lungs of the same set of animals [22] .
Neurological Outcome
In correspondence with the observed brain lesion development, neurological impairments were most severe during the first days, followed by partial recovery. Animals in the interferon-b treatment group did not exhibit an improvement in neurological outcome, which is in line with the lack of a beneficial impact of interferon-b on progression of brain injury. In fact, interferon-b-treated animals scored considerably lower on the behavioral tests. Moreover, case fatality was somewhat higher in the interferon-b treatment group, i.e., 63 % vs. 50 % in the vehicle group. Such high mortality is common in this SAH model [18] and corresponds with an average SAH case fatality of about 50 % in human patients [1] . The high case-fatality may have an impact on the results; however, the power-calculation was already adapted on this case-fatality. The higher case fatality after interferon-b administration was not caused by a larger amount of blood deposition, which in fact was lower in the interferon-b treatment group. A possible deterioration of the animal's condition associated with interferon-b treatment may explain a higher case fatality and lower neurological score. In fact, animals had significantly more weight loss after interferon-b treatment, which corresponds with data from Maier et al. [23] , who also reported considerable weight loss and lack of infarct reduction in rats that received repeated injections of interferon-b (with comparable dosage as in our study) after transient unilateral occlusion of the MCA. Although it remains to be elucidated how possible systemic effects may influence its therapeutic effects on neuroinflammation, hepatic injury has been implicated as a potential critical side effect of interferon-b administration in MS patients [24] . Also, treatment with interferon-b may reduce immunity and increase infection and by that means increase case-fatality. Unfortunately we do not have information on infection rate, e.g., sputum colonization.
Conclusion
Our study did not reveal a neuroprotective effect of interferon-b in an experimental SAH model in rats. This negative result, however, is an important finding with regards to recent emphasis on eliminating publication bias in preclinical stroke treatment studies [20, 25] . Despite encouraging findings in models of experimental cerebral ischemia, our data currently do not recommend clinical evaluation of interferon-b treatment in SAH patients.
